Medscape Dermatology Podcast

Dr Jeffrey S. Weber reviews data from an open-label phase 1/2 trial assessing the efficacy and safety of combination pembrolizumab and reduced-dose ipilimumab in patients with advanced melanoma.

Dr Paul Offit compares Shingrix with Zostavax® and lays out the recommendations for the new vaccine.

Dr Eric Topol discusses factors behind a predicted physician shortage (or lack thereof) with policy expert and ethicist Dr Ezekiel Emanuel.

This combination produced impressive response and disease control rates with good tolerability in treatment-naive patients with advanced melanoma.

New at ESMO 2017, adjuvant dabrafenib/trametinib in stage III melanoma shows 'impressive' results in relapse-free survival.

Dr Arefa Cassoobhoy highlights one of the week's important news stories for primary care.

Dr Frank Veith explains the advantage of MDs and industry working together to create innovative products and improve education while criticizing regulations that restrict the MD/industry relationship.

Dr Arefa Cassoobhoy highlights one of the week's important news stories for primary care.

Physicians from all over the country tell Medscape about their experiences with the ACA. What's your take?

Reviewing recent research, Dr Jeffrey Weber concludes that an amalgam of host- and tumor-related markers will be the best indication of which patients should receive checkpoint inhibitors.